Michael Burkes Brophy Sells 1,442 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 1,442 shares of Natera stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $161.87, for a total value of $233,416.54. Following the sale, the chief financial officer now directly owns 108,032 shares in the company, valued at $17,487,139.84. The trade was a 1.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Trading Up 4.8 %

Shares of NASDAQ:NTRA traded up $8.01 during trading on Thursday, hitting $176.23. 1,429,455 shares of the company's stock were exchanged, compared to its average volume of 1,400,429. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market cap of $23.27 billion, a P/E ratio of -100.13 and a beta of 1.65. The firm has a 50-day moving average price of $166.56 and a two-hundred day moving average price of $137.43. Natera, Inc. has a 1-year low of $64.74 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. During the same period in the previous year, the firm earned ($0.95) earnings per share. The firm's quarterly revenue was up 63.9% compared to the same quarter last year. Equities analysts predict that Natera, Inc. will post -1.56 earnings per share for the current year.

Institutional Trading of Natera

A number of hedge funds have recently modified their holdings of NTRA. Blue Trust Inc. increased its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Quarry LP raised its stake in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock worth $34,000 after buying an additional 190 shares during the period. Versant Capital Management Inc raised its stake in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after buying an additional 166 shares during the period. Covestor Ltd lifted its holdings in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after acquiring an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock valued at $55,000 after acquiring an additional 106 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Piper Sandler lifted their price objective on Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a report on Monday, November 18th. TD Cowen lifted their price target on shares of Natera from $155.00 to $175.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Robert W. Baird upped their price objective on shares of Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. StockNews.com lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Thursday, November 14th. Finally, JPMorgan Chase & Co. increased their price target on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.